

# Coordinating Multidisciplinary Care in High-Risk CSCC

Clarifying specialty roles, coordination points, and shared responsibilities across the patient journey



## Roles and Responsibilities Across the Patient Journey

|                                         | PATIENT JOURNEY                                                        |                                              |                                                        |                                   |
|-----------------------------------------|------------------------------------------------------------------------|----------------------------------------------|--------------------------------------------------------|-----------------------------------|
|                                         | Diagnosis & Risk Assessment                                            | Local Treatment                              | Adjuvant Evaluation                                    | Ongoing Management & Surveillance |
| Dermatology/Mohs Surgery                | Biopsy and diagnosis<br>Patient counseling<br>Initial risk recognition | Mohs surgery (where appropriate)             | Escalation identification<br>Referral initiation       | AE management                     |
| Head & Neck Surgery (Surgical Oncology) | Assess complex anatomy                                                 | Local excision (where appropriate)           | Nodal evaluation                                       | Follow-up                         |
| Pathology                               | Pathology review                                                       |                                              |                                                        | Review as needed                  |
| Radiology                               | Imaging review                                                         |                                              |                                                        | Review as needed                  |
| Radiation Oncology                      | Assess RT candidacy                                                    | Local control planning and RT administration | Re-irradiation discussion                              | Toxicity monitoring               |
| Medical Oncology                        |                                                                        |                                              | Systemic therapy evaluation<br>Risk/benefit discussion | Toxicity monitoring               |
| Critical Coordination Touchpoints       | REFERRAL TIMING                                                        |                                              |                                                        |                                   |
|                                         | SHARED PATIENT COUNSELING                                              |                                              |                                                        |                                   |
|                                         | IMAGING COORDINATION                                                   |                                              |                                                        |                                   |
|                                         | TOXICITY MONITORING & COMMUNICATION                                    |                                              |                                                        |                                   |
|                                         |                                                                        |                                              |                                                        | FOLLOW-UP OWNERSHIP               |

## Real-World Coordination Challenges

- Referral delays
  - Geographic limitations
  - Community vs academic access
- Specialty silos
  - Communication gaps

Coordinated multidisciplinary care for high-risk CSCC should be tailored to each patient’s risk, needs, and preferences.

### REFERENCES

1. Alam M, et al. *J Am Acad Dermatol*. 2018;78(3):560-578.
  2. Trager MH, et al. *J Am Acad Dermatol*. 2026;94(3):914-923.
3. Paradela de la Morena S, et al. *Actas Dermosifilogr*. 2026;117(6):104612.
  4. Claveau J, et al. *Curr Oncol*. 2020;27(4):e399-e407.